May 5, 2026 — Leads & Copy —
Revvity, Inc. (NYSE: RVTY) reported its financial results for the first quarter, which ended April 5, 2026, today.
The company reported GAAP earnings per share from continuing operations of $0.37, compared to $0.35 for the same period last year. Revenue for the quarter totaled $711 million, compared to $665 million for the same period last year. GAAP operating income from continuing operations for the quarter was $76 million, compared to $72 million for the same period last year. The GAAP operating profit margin from continuing operations was 10.7% of revenue, compared to 10.9% last year.
Adjusted earnings per share from continuing operations for the quarter was $1.06, compared to $1.01 last year. Adjusted operating income totaled $168 million, compared to $170 million for the same period last year. The adjusted operating profit margin was 23.6% of revenue, compared to 25.6% last year.
Revvity announced its intention to divest its Immunodiagnostics business in China. This business accounted for about 6% of the company’s total revenue in fiscal year 2025. The company has signed a letter of intent with a potential buyer, with a definitive agreement expected in the second quarter of 2026. The divestiture should be complete in 2027, pending the receipt of required regulatory approvals.
The company is providing first quarter 2026 financial results on both a reported and pro forma basis. Forward-looking guidance is being provided on a pro forma basis, which excludes the business Revvity intends to divest. Management will offer additional commentary and perspective on this strategic action on the company’s first quarter 2026 earnings conference call this morning.
Pro forma earnings per share from continuing operations for the quarter was $0.40, compared to $(0.13) last year. Pro forma operating income was $80 million, compared to $20 million last year. The pro forma operating profit margin was 11.7% of pro forma revenue, compared to 3.2% last year.
On a pro forma adjusted basis, earnings per share for the quarter was $1.04, compared to $0.95 last year. Pro forma revenue for the quarter was $687 million, compared to $629 million last year. Pro forma adjusted operating income was $165 million, compared to $159 million last year. The pro forma adjusted operating profit margin was 24.0% of pro forma revenue, compared to 25.3% last year.
Adjustments for the company’s non-GAAP financial measures have been noted in the attached reconciliations.
Prahlad Singh, president and chief executive officer of Revvity, said the company performed well in the first quarter, with organic growth and adjusted EPS exceeding expectations due to strong execution from teams across the organization. He added that their disciplined approach to portfolio optimization positions them well to capitalize on improving market conditions and deliver differentiated results for shareholders.
In the Life Sciences segment, first quarter 2026 revenue was $362 million, compared to $340 million last year. Revenue increased 6%, and organic revenue and pro forma organic revenue increased 3% compared to last year. First quarter 2026 adjusted operating income was $104 million, compared to $106 million last year. The adjusted operating profit margin was 28.7% of revenue, compared to 31.1% last year.
In the Diagnostics segment, first quarter 2026 revenue was $349 million, compared to $324 million last year. Revenue increased 8%, and organic revenue increased 4% compared to last year. Pro forma organic revenue increased 9% compared to last year. First quarter 2026 adjusted operating income was $76 million, compared to $74 million last year. The adjusted operating profit margin was 21.8% of revenue, compared to 22.8% last year.
For the full year 2026, on a pro forma basis, the company forecasts total revenue of $2.81-$2.84 billion, pro forma organic revenue growth of 3%-4%, and pro forma adjusted earnings per share of $5.20-$5.30.
The company will discuss its first quarter 2026 results and its outlook for business trends during a webcast on May 5, 2026, at 7:30 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the company’s website, ir.revvity.com.
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.
Stay updated by following their Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
Source: Revvity
